First, we aimed to construct a PBPK model for SGLT2 inhibitors combined with the mathematical model of UGE, and simulate and validate the PK and PD of SGLT2 inhibitors in both healthy subjects and T2DM patients with renal insufficiency. The gene discussed is SLC5A2; the disease is Renal insufficiency.